Abstract     Description     Claims     Drawing  

US61810468A   [0001] 
US61925918A   [0001] 
US4997878A   [0015] 
US5037883A   [0015] 
US5258453A   [0015]  [0211] 
US6464850B   [0015] 
US6803438B   [0015] 
US20040116348A   [0016]  [0017] 
US7553816B   [0016]  [0017] 
US7223837B   [0016] 
US6759509B   [0016] 
US6835807B   [0016]  [0017] 
US6436912B   [0016] 
US7943569B   [0016] 
US6291671B   [0017] 
US6811996B   [0017] 
US7041818B   [0017] 
US7091186B   [0017] 
US6242494B   [0090] 
US6063812A   [0090] 
US6887863B   [0090] 
US7030262B   [0090] 
US7491718B   [0090] 
WO2010003475A   [0090] 
US2803586A   [0091] 
US5166172A   [0091]  [0093]  [0211] 
WO2011150088A   [0131] 
WO2011150022PCT   [0131] 
US6548477B   [0195] 
WO2011150022A   [0321]  [0333] 

Metabolic Syndrome and Related Disorders   [0003] 
Nutr. Metab. Cardiovasc. Dis.   [0003] 
Circulation   [0003] 
J. Am. Coll. Cardiol.   [0003] 
J Controlled Release   [0015] 
Release from Polymeric Prodrugs: Linkages and Their Degradation   [0016] 
Self-immolative linkers in polymeric delivery systems   [0016] 
Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies   [0016] 
Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models   [0016]  [0017] 
Biol. Pharm. Bull.   [0016]  [0017] 
Bioconjugate Chem.   [0016]  [0017] 
Trends in Cell Biology   [0019] 
Correlation of tumor growth suppression and methionine aminopeptidase-2 activity blockade using an orally active inhibitor   [0090] 
Design, Synthesis, and Antiangiogenic Effects of a Series of Potent Novel Fumagillin Analogues   [0090] 
Total synthesis and antiangiogenic activity of cyclopentane analogues of fumagillol   [0090] 
Carbamate Analogues of Fumagillin as Potent, Targeted Inhibitors of Methionine Aminopeptidase-2   [0090] 
The Stereochemistry of Fumagillin   [0091] 
Ectopic Expression of Methionine Aminopeptidase-2 Causes Cell Transformation and Stimulates Proliferation   [0092] 
Fumagillin class inhibitors of methionine aminopeptidase-2   [0093] 
Adipose tissue mass can be regulated through the vasculature   [0094] 
The Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice   [0094] 
Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732   [0094] 
Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity   [0094] 
TNP-470: The Resurrection of the First Synthetic Angiogenesis Inhibitor   [0095] 
Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined with Paclitaxel in Patients with Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer   [0095] 
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung Cancer   [0096] 
A Phase 1 pharmacokinetic and pharmacodynamics study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer   [0096] 
Handbook of Chemistry and Physics   [0102] 
Biochemistry   [0124] 
Peptides and Amino Acids   [0125] 
March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure   [0130] 
Protective Groups in Organic Synthesis   [0130] 
Pharmaceutical Salts   [0135] 
Design of Prodrugs   [0138] 
Int. J. Obes. Relat. Metab. Disord.   [0165] 
Current Protocols in Molecular Biology   [0208] 
Molecular Cloning, A Laboratory Manual   [0208] 
Current Protocols in Immunology   [0208] 
Current Protocols in Pharmacology   [0208] 
The Pharmacological Basis of Therapeutics   [0208] 
Remington's Pharmaceutical Sciences   [0208] 
Biorg. Med. Chem. Lett.   [0211] 
Diabetologia   [0315] 
British Journal of Pharmacology   [0315] 
Am J Physiol Regul Integr Comp Physiol.   [0316] 
A Mouse Model of Metabolic Syndrome   [0329] 
Diabetes Care   [0329]